GILEAD SCIENCES, INC. Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss)
GILEAD SCIENCES, INC. (GILD) reported Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss) of -$7.00 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-06.
Discontinued › Income Statement › Other Income
us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss · last filed 2020-05-06
- GILEAD SCIENCES, INC. finite lived intangible assets, foreign currency translation gain (loss) for the quarter ending 2020-03-31 was -$7.00M.
- GILEAD SCIENCES, INC. finite lived intangible assets, foreign currency translation gain (loss) for the quarter ending 2019-12-31 was $1.00M.
- GILEAD SCIENCES, INC. finite lived intangible assets, foreign currency translation gain (loss) for the quarter ending 2019-09-30 was -$4.00M, a 300.00% decline year-over-year.
- GILEAD SCIENCES, INC. finite lived intangible assets, foreign currency translation gain (loss) for the quarter ending 2019-06-30 was $1.00M.
- GILEAD SCIENCES, INC. finite lived intangible assets, foreign currency translation gain (loss) for fiscal 2018 was -$3.00M.
| Period end | Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss) 3 month | Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss) 6 month | Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss) 9 month | Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss) 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$7.00M 10-Q · filed 2020-05-06 | -$6.00M derived: sum of 2 quarters · filed 2020-05-06 | -$10.00M derived: sum of 3 quarters · filed 2020-05-06 | -$9.00M derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-12-31 | $1.00M derived: 10-Q 12 month − 10-Q 9 month · filed 2020-05-06 | -$3.00M derived: sum of 2 quarters · filed 2020-05-06 | -$2.00M derived: sum of 3 quarters · filed 2020-05-06 | -$6.00M 10-Q · filed 2020-05-06 |
| 2019-09-30 | -$4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$3.00M derived: sum of 2 quarters · filed 2019-11-05 | -$7.00M 10-Q · filed 2019-11-05 | -$9.00M derived: sum of 4 quarters · filed 2020-02-25 |
| 2019-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$3.00M 10-Q · filed 2019-08-06 | -$5.00M derived: sum of 3 quarters · filed 2020-02-25 | -$3.00M derived: sum of 4 quarters · filed 2020-02-25 |
| 2019-03-31 | -$4.00M 10-Q · filed 2019-05-08 | -$6.00M derived: sum of 2 quarters · filed 2020-02-25 | -$4.00M derived: sum of 3 quarters · filed 2020-02-25 | -$11.00M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | -$7.00M derived: sum of 3 quarters · filed 2020-02-25 | -$3.00M 10-K · filed 2020-02-25 |
| 2018-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$5.00M derived: sum of 2 quarters · filed 2018-11-06 | -$1.00M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | -$7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | -$3.00M 10-Q · filed 2018-08-06 | ||
| 2018-03-31 | $4.00M 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |